Exploring the human experience of congenital aniridia: A narrative medicine approachShow others and affiliations
2026 (English)In: European Journal of Ophthalmology, ISSN 1120-6721, E-ISSN 1724-6016, Vol. 36, no 3, p. 601-608Article in journal (Refereed) Published
Abstract [en]
Purpose To explore the emotional and social burden of congenital aniridia in patients and caregivers through narrative medicine.Methods Patients with congenital aniridia and their caregivers were enrolled in a multicentric observational study. Sociodemographic data and personal narratives were collected through interviews or written accounts. A qualitative analysis was conducted and overarching themes identified.Results A total of 57 narratives were collected (31 patients, 27 caregivers). Participants reported visiting an average of 5.1 +/- 5.9 healthcare facilities over their lifetime. Aniridia impacted work or school life in 39% of patients and 58% of caregivers. Most narratives focused on the lived experience of illness (95% patients, 81% caregivers) or on social perception (48% and 46%), rather than on clinical aspects (10% and 23%). Adaptation to the disease was mainly stable or progressive among adults. Emerging themes included independence, feeling misunderstood, and bullying. Caregivers emphasized the lack of specialized centers, standardized protocols, adequately trained professionals, psychological and practical support, and the lack of humanity among doctors.Conclusions Congenital aniridia leads to progressive visual impairment with significant emotional and social consequences. Narrative medicine offers valuable insight into patients' and caregivers' lived experiences, highlighting unmet needs and concerns often overlooked in conventional clinical practice.
Place, publisher, year, edition, pages
SAGE PUBLICATIONS LTD , 2026. Vol. 36, no 3, p. 601-608
Keywords [en]
Congenital aniridia; narrative medicine; narratives; patients; caregivers
National Category
Ophthalmology
Identifiers
URN: urn:nbn:se:liu:diva-220432DOI: 10.1177/11206721251407851ISI: 001639548100001PubMedID: 41400928Scopus ID: 2-s2.0-105025013897OAI: oai:DiVA.org:liu-220432DiVA, id: diva2:2028801
Note
Funding Agencies|COST Action CA-18116 ANIRIDIA NET
2026-01-152026-01-152026-05-21